
- Vol 43, Issue 11
Ketamine for Treatment-Resistant Depression: Practical Clinical Considerations
Clinicians weigh ketamine vs FDA-approved esketamine for TRD, with evolving guidance on dosing, safety monitoring, and long-term maintenance decisions.
Ketamine and esketamine have become important treatment options for treatment-resistant depression (TRD). Although their acute antidepressant efficacy is well established, many decisions clinicians face in routine practice are supported by less evidence. These uncertainties are especially relevant to intravenous (IV) racemic ketamine, which remains an off-label treatment for depression, with substantial variation in dosing and maintenance practices.1 Intranasal esketamine, in contrast, holds FDA-approved indications for treatment of TRD and major depressive disorder associated with suicidal ideation. Esketamine must be administered under a risk evaluation and mitigation strategy (REMS), which standardizes dosing and requires a registry that collects data on use patterns and adverse events. As a result, its long-term evidence base is substantially larger.2,3
Patient Selection
The most extensive, high-quality evidence supporting psychiatric use of ketamine and esketamine is in depressive disorders, particularly
Ketamine and esketamine may be particularly useful when rapid improvement is important, including in patients with substantial suicidal ideation.6 Although suicidal ideation is generally found to be meaningfully reduced in trials, it has been difficult to reliably show reductions in suicidal ideation compared with control treatments. Even more important, evidence that these treatments reduce suicide attempts or deaths remains insufficient, strongly supporting the idea that patients being treated with ketamine or esketamine should be incorporated into comprehensive suicide-risk management programs.
To best assess the potential risk-benefit ratio of treatment, clinicians should confirm the diagnosis and adequacy of previous treatment trials. Medication reconciliation is important for safety; in our practice, for example, we generally hold stimulants and opioids on treatment days to mitigate cardiovascular or respiratory risks. Patients with a history of psychosis, cardiovascular disease, mania, or substance use disorders warrant individualized risk-benefit assessment, although they should not necessarily be excluded from treatment. We make a similar individualized evaluation of patients with documented neurological and neurodegenerative disorders such as Parkinson disease.
Induction and Dose Optimization
Recent consensus guidelines support approximately 4 to 6 IV ketamine infusions over 2 to 4 weeks, generally beginning at 0.5 mg/kg administered over approximately 40 minutes. Current evidence provides no support for dosing more frequently than twice weekly,7 and safety and efficacy data for doses greater than 1 mg/kg remain limited.1
Esketamine follows a more standardized treatment paradigm, with a 4-week twice-weekly induction followed by progressively less frequent treatment for TRD.8 Doses of 56 and 84 mg are used for TRD, with available trials demonstrating efficacy at both doses without a consistent dose-response advantage for 84 mg.9,10 Thus, dose selection should be guided by clinical response and tolerability rather than routine escalation. For MDD with acute suicidal ideation or behavior, the labeled regimen is 84 mg twice weekly, with reduction to 56 mg based on tolerability.8
A recent randomized trial demonstrating efficacy of esketamine monotherapy over placebo led to expansion of the FDA indication to include monotherapy for TRD.8,9 However, the more extensive evidence base remains for esketamine used with an oral antidepressant, including the phase 3 trials supporting its initial FDA approval in 2019.10-14 In our practice, we generally continue an oral antidepressant when tolerated, reserving monotherapy for patients who truly cannot tolerate oral antidepressants or find little apparent benefit from continuing one.
Dose optimization requires thoughtful clinical judgment and should be informed by measurement-based care. In our practice, we assess outcomes at specific intervals (eg, treatments 4, 8, and 12) using validated depression rating scales to guide clinical decision-making. If a patient has not meaningfully improved after an adequate induction, clinicians should not assume that more treatments or higher doses will eventually produce a therapeutic response, and escalation should not be the default approach to inadequate clinical improvement. The relationship between dissociation and antidepressant efficacy remains uncertain, and increasing the dose primarily to intensify the subjective experience may increase adverse effects without improving effectiveness. Additionally, patient expectations may also influence treatment response.15,16 Clinicians should therefore be mindful of how they discuss treatment and how they may shape these expectations.
Safety Monitoring
The acute effects of ketamine are generally predictable and transient. With esketamine, we now have safety data published on nearly 1.5 million dosing sessions in real-world settings as a result of the mandatory REMS.3 Commonly encountered adverse effects include dissociation, dizziness, nausea, sedation, and increases in blood pressure.8 Most can be managed with observation and supportive care, but clinicians should be prepared to potentially address clinically significant cardiovascular events, substantial sedation or behavioral changes, anxiety, and nausea and vomiting.
Unlike esketamine, racemic ketamine is not administered within a standardized FDA labeling and REMS framework, leaving greater responsibility to individual programs to establish appropriate monitoring practices. In our clinic, we apply similar principles to both treatments and have adopted standardized practices to optimize patient monitoring and safety. For ongoing treatment, more comprehensive clinical assessments should occur at predetermined intervals to assess not only depressive symptoms and functioning but also cognition, urinary symptoms, changes in substance use, and evidence of treatment tolerance.
Beyond Symptom Reduction
Although the added benefit of concomitant psychotherapeutic treatments with ketamine or esketamine has not been reliably demonstrated, there is growing interest in combining these approaches.17 Emerging studies suggest cognitive and behavioral-focused interventions may complement ketamine treatment, potentially leveraging periods of enhanced neuroplasticity and cognitive flexibility, although the optimal type and timing of
Treatment Maintenance
For patients who respond to IV ketamine, maintenance evidence remains limited. A 2026 systematic review identified 11 maintenance studies and found generally sustained antidepressant benefit and acceptable tolerability, but considerable heterogeneity in treatment protocols.19 Maintenance IV ketamine is therefore reasonable for selected responders, but optimal frequency and duration remain uncertain. Some patients maintain benefit as intervals are extended, whereas others experience predictable recurrence or worsening symptoms. In our clinic, maintenance frequency is continually reassessed with attempts to extend treatment intervals or stop altogether when clinically feasible. Again, it is important to consider how psychological factors such as conditioning and expectations may contribute to the likelihood of sustained benefit and relapse, and that prospective use of relapse prevention strategies may be beneficial.
Long-term evidence is considerably more extensive for esketamine. In the final SUSTAIN-3 analysis, 1148 adults with TRD received intermittently dosed esketamine plus an oral antidepressant for up to 6.5 years, representing 3777 patient-years of exposure. Mean exposure was 42.9 months, approximately half of the participants were in remission at the maintenance end point, and no new safety signals were identified.2 Although its open-label design limits causal conclusions, its duration and cumulative exposure substantially exceed those available for IV racemic ketamine.
How Much Exposure Is Too Much?
In SUSTAIN-3, weekly and every-other-week dosing accounted for most maintenance treatment, with some participants treated for more than 6 years.2 Frequent maintenance exposure itself should therefore not necessarily be viewed as concerning when supported by continued benefit.
At the same time, a recent review highlighted neuronal injury and persistent cognitive deficits with repeated or higher-dose ketamine exposure in several animal models.20 The relevance of these findings to therapeutic human exposure remains uncertain, and clinical esketamine data have not demonstrated comparable cognitive deterioration. These findings should neither be dismissed nor interpreted as evidence that therapeutic ketamine causes neurotoxicity; rather, they caution against extrapolating available safety data to substantially different doses, frequencies, or treatment paradigms.
In our own research experience, the FDA has required limiting IV ketamine administration to a maximum total dose of 60 mg per administration, with a maximum of 8 administrations for clinical trials, before issuing a “safe to proceed” letter for investigational new drug applications. This should not be interpreted as an established FDA dosing limit for clinical practice, but illustrates the caution applied to higher absolute exposures even in controlled research settings based on the limited existing safety data that has been reviewed by the agency.
Implications for Clinical Practice
The evidence supporting acute ketamine treatment is substantial,4 but the more difficult questions often arise after patients respond. Maintenance IV ketamine appears effective for some patients, but optimal frequency and duration remain uncertain,19 whereas long-term prospective and real-world data provide greater reassurance for repeated esketamine within established dosing paradigms.2,3 For maintenance treatment, symptoms and functioning should be followed longitudinally, treatment intervals extended when feasible, and cumulative exposure and emerging adverse effects periodically reconsidered.
The question of whether and when to discontinue esketamine treatment after achieving a response remains perplexing. However, decisions can be informed by SUSTAIN-1, which suggested that participants who achieved stable remission were less likely to relapse following esketamine discontinuation than those who achieved a stable response without remission.13 Our goal is not to continue ketamine indefinitely, but to ensure that each phase of treatment offers more benefit than risk.
Dr Hughes is an assistant professor of psychiatry at the Yale School of Medicine and an attending psychiatrist on the Yale New Haven Hospital Interventional Psychiatry Service.
Dr Sanacora is the George D. and Esther S. Gross Professor of Psychiatry at the Yale School of Medicine and the director of the Yale Depression Research Program. He is also the codirector of the Yale New Haven Hospital Interventional Psychiatry Service.
References
1. Mathai DS, Cluck M, Aslam AM, et al.
2. Zaki N, Chen LN, Lane R, et al.
3. Sanacora G, Ahmed M, Brown B, et al.
4. Nikolin S, Rodgers A, Schwaab A, et al.
5. Kwan ATH, Lakhani M, Singh G, et al.
6. Chen CC, Zhou N, Hu N, et al.
7. Singh JB, Fedgchin M, Daly EJ, et al.
8. Spravato (esketamine) nasal spray, CIII. Prescribing information. Janssen Pharmaceuticals, Inc; 2025.
9. Janik A, Qiu X, Lane R, et al.
10. Fedgchin M, Trivedi M, Daly EJ, et al.
11. Popova V, Daly EJ, Trivedi M, et al.
12. Ochs-Ross R, Daly EJ, Zhang Y, et al.
13. Daly EJ, Trivedi MH, Janik A, et al.
14. Wajs E, Aluisio L, Holder R, et al.
15. Rutherford BR, Wall MM, Brown PJ, et al.
16. Matsingos A, Wilhelm M, Noor L, et al.
17. Moore TM, Walker K, Tung E, et al.
18. Hardy MS, Li SW, Wilkinson ST.
19. Al-Garni AM, Vazquez G, Alotibi T, et al.
20. Li SW, Kumpf KT, Urrutia J, et al.
Articles in this issue
Related to this article








